Articles Vol. 67 No. CĐ6-NCKH 16/06/2026

SUCCESSFUL DESENSITIZATION TO D-PENICILLAMINE IN A PATIENT WITH DRUG HYPERSENSITIVITY DURING TREATMENT FOR WILSON’S DISEASE

Chu Hong Hanh1,2, Dang Thi Cam Bang1,2, Le Huyen Trang1,2, Nguyen Thi Van Anh1,2
1 Department of Immunology - Allergy - Rheumatology, National Children's Hospital
2 Khoa Miễn dịch - Dị ứng - Khớp, Bệnh viện Nhi Trung ương
DOI: 10.52163/yhc.v67iCD6.5332
14 Views
0 Downloads
Abstract

Introduction: D-penicillamine is a chelating agent commonly used in the treatment of Wilson disease; however, it may cause delayed hypersensitivity reactions, typically occurring several weeks after initiation.

Case presentation: A 14-year-old girl with Wilson disease developed a generalized morbilliform rash with pruritus after 7 days of D-penicillamine therapy. Patch testing performed 4 weeks later yielded a positive result, suggesting a delayed hypersensitivity reaction. Due to limited access to alternative agents such as trientine, a slow desensitization protocol to D-penicillamine was selected based on clinical experience, with corticosteroid premedication and antihistamines administered as needed. During desensitization, the patient experienced a mild rash that was well controlled. After 40 days, she successfully tolerated a therapeutic dose of 900 mg/day and continued outpatient treatment.

Conclusion: This case suggests that patch testing may aid in the diagnosis of delayed hypersensitivity to D-penicillamine, and that slow desensitization may be a feasible option in settings where alternative therapies are not readily available; however, further studies are needed to evaluate its safety and efficacy.

References
[1]
Schilsky ML, Roberts EA, Bronstein JM, Dhawan A, Hamilton JP, Rivard AM, Washington MK, Weiss KH, Zimbrean PC. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2025 Sep 1;82(3):E41-E90. Google Scholar
[2]
Kumar S, Patra BR, Irtaza M, Rao PK, Giri S, Darak H, Gopan A, Kale A, Shukla A. Adverse Events with D-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit. Clin Drug Investig. 2022 Feb;42(2):177-184. Google Scholar
[3]
Abbas, O., & Ishak, R. (2013). Penicillamine Revisited: Historic Overview and Review of the Clinical Uses and Cutaneous Adverse Effects. American Journal of Clinical Dermatology, 14(3), 223–233. Google Scholar
[4]
Grasedyck K. D-Penicillamin--Nebenwirkungen, Pathogenese und Risikominderung [D-penicillamine--side effects, pathogenesis and decreasing the risks]. Z Rheumatol. 1988;47 Suppl 1:17-9. Google Scholar
[5]
Anuntrangsee T, Chanprapaph K, Iamsumang W. D-Penicillamine-Induced Stevens-Johnson Syndrome in a Patient with Gold Cyanide Intoxication: A Case Report. Clin Cosmet Investig Dermatol. 2024 Oct 28;17:2409-2415. Google Scholar
[6]
Honma T, Nakayama Y. D-penicillamine-induced enhancement of the delayed hypersensitivity reaction in guinea-pigs. Ann Rheum Dis. 1982 Feb;41(1):90-2. Google Scholar
[7]
Metushi IG, Zhu X, Uetrecht J. D-penicillamine-induced granulomatous hepatitis in brown Norway rats. Mol Cell Biochem. 2014 Aug;393(1-2):229-35. Google Scholar
[8]
Krishna MT, Huissoon AP. Clinical immunology review series: an approach to desensitization. Clin Exp Immunol. 2011 Feb;163(2):131-46. Google Scholar
[9]
Vultaggio A, Matucci A, Nencini F, Bormioli S, Vivarelli E, Maggi E. Mechanisms of Drug Desensitization: Not Only Mast Cells. Front Pharmacol. 2020 Dec 23;11:590991. Google Scholar
[10]
Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, Schnyder B, Whitaker P, Cernadas JS, Bircher AJ; ENDA, the European Network on Drug Allergy and the EAACI Drug Allergy Interest Group. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013 Jul;68(7):844-52. Google Scholar